A Phase 3 clinical trial evaluating survodutide (BI 456906) has been updated to completed status as of August 6, 2026. The study, registered as NCT06066528, is titled "A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight."
The trial was designed to examine survodutide in participants living with overweight or obesity who also have diabetes. According to the registry entry, the trial has now reached completed status at the Phase 3 stage.
Survodutide remains classified as an unapproved compound under research investigation. This update reflects only the change in trial status and does not indicate whether results have been posted or what those results show.
No outcome data, efficacy figures, or safety findings are included in this status update. Readers should refer directly to the trial registry at the provided identifier for any future posting of results or additional study details.
For more background on survodutide, including its research status and mechanism, see the compound overview.